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Prolonged hyperglycemia in diabetes mellitus results in severe vascular complications leading to decrease in 
longevity of affected individuals. Diabetic retinopathy is a major cause of blindness in diabetes. Nobiletin is a 
polymethoxyflavone present in high concentration in citrus fruits. Here we have evaluated the treatment with 
nobiletin on the amelioration of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetes was induced 
by a single intraperitoneal administration of STZ (50 mg/kg). Animals with blood glucose levels >350mg/dL after 
48 hours of STZ injection were subjected to further treatments. Diabetic rats were treated daily with nobiletin 
(10 mg/kg and 25 mg/kg) for four weeks after four weeks of induction of diabetes. At the end of eight 
weeks, blood retinal barrier permeability was quantified in animals treated with nobiletin and compared with that 
of vehicle control. Histopathological analysis of the retinal sections was done using H&E stain and the outer 
limiting membrane to inner limiting membrane distance was measured. Further, outer nuclear membrane 
thickness was compared between the treatment groups.  The study suggested that nobiletin reduced blood 
retinal barrier permeability and improved the thickness of retinal layers. Thus, treatment with nobiletin can be 
used as an approach to ameliorate diabetic retinopathy. 
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Introduction 
Diabetic retinopathy (DR) is a slow-
progressing, multifactorial microvascular complication 
of diabetes and is the major cause of blindness 
affecting 80% of diabetic individuals worldwide.  The 
incidence of DR at the time of the diagnosis of 
diabetes is much lower with type I diabetes mellitus 
(0.4%) than type II diabetes mellitus (7.6%).1 
Prolonged hyperglycemia in diabetes leads to the 
activation of alternative pathways for excessive 
circulating glucose, which on long term, affect the 
ocular vasculature leading to retinal vascular defects 
and neuroretinal dysfunction and degeneration. The 
exact mechanism by which hyperglycemia causes 
blindness remains incompletely understood. Probable 
mechanisms of ocular vasculature disruption include 
the intraocular formation of reactive oxygen species 
that lead to pathological and biochemical changes like 
protein glycation2 and  protein kinase-C activation 
which may lead to enhanced permeability of retinal 
vasculature, endothelial growth factors (VEGF) and 
cellular signalling by vascular basement membrane 
thickening.3,4  Matrix metalloproteinases (MMPs), 
specifically MMP-2 and MMP-9 that are involved in 
modulation of extracellular matrix (ECM)  have shown 
to play a role in the retinal neovascularization seen in 
the later stages of diabetic retinopathy.5,6 
MMPs is a family of over 25 zinc-dependent 
proteinases which degrade different components of 
the extracellular matrix (ECM) and regulate many 
normal and pathological processes.7 Several studies 
have indicated that the gelatinases, specifically MMP-2 
and MMP-9, are increased in the epiretinal neovascular 
membranes of patients with proliferative diabetic 
retinopathy8 as well as in retinas in an animal model of 
retinal neovascularization.9 MMP-2 and MMP-9 have 
also been shown to have significantly increased levels 
of activation in vitreous samples from individuals with 
proliferative diabetic retinopathy.10 Recent research 
has shown that MMPs have a dual role in the 
development of diabetic retinopathy; in the early 
stages of the disease (pre-neovascularization), MMP-2 
and MMP-9 facilitate the apoptosis of retinal capillary 
cells, possibly via damaging the mitochondria, and in 
the later phase, they help in neovascularization.11.  
Several natural flavonoids have shown to 
possess MMP inhibitory activity. Nobiletin, a 
polymethoxy flavone present in high concentrations in 
peels of citrus fruits, is reported for its many potential 
health benefits.12 The present study aimed at 
evaluating the benefits of long term administration of 
Nobiletin ameliorates streptozotocin induced diabetic 
retinopathy in experimental rats 
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nobiletin in STZ induced diabetic retinopathy. Since 
nobiletin is a potential molecule with MMP inhibitory 
effects seen in cancer cell lines,12 treatment with 
nobiletin could be beneficial in amelioration of 
diabetic retinopathy in experimental animals. 
  
Materials and methods 
Materials and chemicals 
Streptozotocin (STZ) was purchased from 
Sigma Aldrich (St. Louis MO, USA). Nobiletin was 
purchased from Baoji Hongyuan Biotechnology Co. 
Ltd. (Baoji City, China).  A gift sample of Minocycline 
was received from US Vitamins (Mumbai, India). All 
the biochemical diagnostic kits were procured from 
Erba Diagnostics (Mumbai, India). All the other 
reagents and chemicals used for the study were of 
analytical grade. 
 
Preparation of drug solution 
STZ was dissolved in ice cold citrate buffer 
(pH 4.5) just before use. Nobiletin and minocycline 
(MINO) were suspended in 0.5% CMC 
(carboxymethyl cellulose) solution before use. 
 
Animals, induction of diabetes and study protocol  
Male Wistar rats (weighing 190–230 gms and 
10-12 wks of age), purchased from Haffkine Institute 
(Lower Parel, Mumbai), were employed in the study. 
Animals were housed in clean environment and 
maintained at a temperature of 25 ± 1C, RH 45-55% 
under a 12 hr light/ dark cycle and had free access to 
food and water ad libitum.  
The study animals were fasted for 12 hrs and 
diabetes was induced using a single dose of STZ (50 
mg/kg, ip). Blood sugar levels (BSL) were checked for 
individual animals 48 hrs after STZ injection and the 
animals with BSL >350 mg/dL were considered 
diabetic and used for further study. The BSL was 
further monitored weekly throughout the eight week 
study period. 
Animals were randomly divided into five 
groups of six animals each. Four weeks after the 
induction of diabetes, oral daily treatment of nobiletin 
was carried out for further four weeks. Group I served 
as normal control (NORMO) with non-diabetic 
normal animals, Group II served as vehicle control 
and received 0.5% CMC solution (1 mL/kg); Group 
III and IV were the treatment groups and received 
nobiletin (NOB) at a dose of 10 mg/kg (NOB10) and 
25 mg/kg (NOB25) respectively; Group V received 
minocycline (MINO) at a dose of 50 mg/kg. 
 
 
Blood retinal barrier permeability 
At the end of eight weeks period, the blood retinal 
barrier (BRB) permeability was measured using an 
Evans blue technique.13 Briefly, rats were anesthetized 
with pentobarbital sodium (45 mg/kg). After 
cannulating left femoral artery and vein, Evans blue 
(45 mg/kg) was injected into the femoral vein. Two 
minutes after the injection of Evans blue, 0.2 ml blood 
was drawn to obtain the initial Evans blue plasma 
concentration. Subsequently, at 15-minute intervals, 
0.1 mL blood was drawn up to 2 hours after injection 
to obtain the time-averaged Evans blue plasma 
concentration. The blood samples were centrifuged at 
12000 rpm for 30 min and the plasma was diluted 
1/10000 in formamide. Absorbance of Evans blue was 
measured by spectrophotometry at 620 nM. The 
concentration of dye in the plasma was calculated 
from a standard curve of Evans blue in formamide. 
Subsequently, the chest cavity was opened, and rats 
were perfused via the left ventricle at 37°C with 60 mL 
citrate buffered paraformaldehyde (1% w/v) over a 2 
min interval to clear Evans blue from the circulation. 
The retina from the eye was collected, dried for 2 h 
and weighed. The Evans blue dye was extracted by 
incubating each retina in 120 mL of formamide for 18 
h at 70 °C. The extract was centrifuged at 14000 g for 
12 min at 25 °C. The absorbance of 80 mL of the 
supernatant was measured by spectrophotometry. The 
BRB permeability was calculated as follows: 
 
[Evans blue (μg)/retina dry weight (g)] / 
[Time-averaged Evans blue concentration (μg)/plasma 
(μL) × circulation time (h)] 
 
Histology and measurement of retinal thickness 
After the BRB measurements, the animals 
were sacrificed with deep anaesthesia. The eyeballs 
were removed and fixed in 10% formaldehyde 
solution. Histopathological analysis was done after 
staining with hematoxylin and eosin (H&E) for light 
microscopy by taking serial sections (5 μM) that 
passed through the optic nerve head and cutting 
marker. Retinal thickness of different layers was 
measured at a 400× magnification, including: (1) outer 
limiting membrane to inner limiting membrane (OLM-
ILM) (2), outer nuclear layer (ONL), and (3) inner 
nuclear layer (INL). Two measurements were taken on 
each section, at the two reference lines which were 1 
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Statistics 
All data are expressed as mean ± SD. Statistical 
analysis was performed using GraphPad Prism 
(version 4.0, Graph Pad Inc., San Diego, USA) 
software. For multiple comparisons, one-way analysis 
of variance (ANOVA) was used. In case ANOVA 
showed significant differences, post-hoc analysis was 
performed with Tukey's test or Dunnet test, p<0.05 
was considered statistically significant. 
 
Results  
Body weight and blood glucose levels 
The body weights and BSL of the animals was 
monitored weekly during the experiment. The weekly 
body weight data of animals indicated that there was a 
decrease in the body weights of animals in the first 
four weeks after STZ injection followed by an increase 
towards the end of eight week. Vehicle control group 
showed lesser recovery of body weights compared to 
treatment groups (Table 1). The BSL of the treatment 
group at the end of eight weeks showed no significant 
decrease compared to vehicle control group (Table 1).  
 
Group 
8 weeks BSL 
(mg/dL) 
8 weeks body 
weight (g) 
NORMO 102.18 ± 11.58** 230.33 ± 8.50** 
DB + 0.5% 
CMC 
553.98 ± 37.72 187.33 ± 10.97 
NOB10 542.65 ± 52.29 182.83 ± 14.57 
NOB25 521.78 ± 48.56 181.33 ± 15.73 
DB + MINO 553.83 ± 27.01 177.67 ± 9.89 
Table 1. Body weight and BSL of animals after 4 wk treatment with 
NOB. The values are given as mean ± S.D.; ** P <0.01 when compared 
with vehicle treated diabetic group. NORMO (Normal Group), DB + 
0.5% CMC (Diabetic group treated with 0.5% CMC), NOB10 (Diabetic 
group treated with Nobiletin 10mg/kg), NOB25 (Diabetic group treated 
with nobiletin 25mg/kg), DB + MINO (Diabetic group treated with 
standard minocycline). 
 
Assessment of BRB permeability 
Evans blue was used to quantitate the degree of 
vascular permeability of the retina. One eye from each 
of the animal was used for the study. At the end of 
eight week study, the vascular permeability of the 
retina was determined and it was observed that there 
was an increase in the retinal vascular permeability in 
the STZ animals compared to the normal control. 
Treatment with NOB25 improved the retinal 
vasculature as seen in reduction of BRB permeability 
(Figure 1). 
 
 Histological analysis of retina 
The retinal sections were taken and morphometric 
analysis was done using H&E stain. It was observed that the 
retinal thickness was compromised in STZ diabetic animals 
compared to normal control.  Primarily, the reduction in 
thickness occurred in the ONL in diabetic rats up to 2 
months (Figure 2). For INL in diabetes, there was no 
significant difference in 2 months diabetes compared with 
normal controls. Treatment NOB25 significantly attenuated 
ONL thickness when compared with vehicle treated 
diabetic group. 
Figure 1. Effect of four week treatment with NOB10 and NOB25 on 
retinal permeability. * p<0.05, ** p<0.01 vs vehicle treated diabetic 
rats. (n = 6 for all groups) 
 
                                                                   
Discussion  
Diabetic retinopathy is a severe complication 
of diabetes characterized by excessive permeability of 
retinal blood vasculature that when left untreated leads 
to blindness. The present study aimed at evaluating the 
effect of nobiletin on STZ induced diabetic 
retinopathy. Comparison of eight week BSL of the 
treatment groups with vehicle control indicated that 
four week treatment with nobiletin at a dose of 10 
mg/kg (NOB10) and 25 mg/kg (NOB25) did not 
have any significant effect on reducing the BSL. Thus, 
it can be stated that nobiletin attenuates diabetic 
retinopathy by other than glucose lowering 
mechanism. 
The blood retinal barrier (BRB) is localized at 
the endothelial cells of the retinal capillary vessels and 
at the epithelial cells of the retinal pigment epithelium. 
The presence of transport processes and the existence 
of tight junctions between the endothelial and the 
epithelial cells that form the BRB prevent the entrance 
of toxic molecules into the retina and the escape of 
important ions from the retina. Thus, BRB has an 
important role in the homeostasis of the retina. 
Breakdown of the BRB is an early feature of diabetic 
retinopathy and results in vascular leakage and the 
development of retinal edema.14-18 STZ induced 
diabetes caused increased permeation of BRB as seen 
in experimental animals of vehicle control group. It 
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animals on treatment with NOB25. Treatment with 
NOB10 did not have any significant effect on BRB 
permeability.  Histological analysis of the retinal 
sections stained with H&E indicated that treatment 
with NOB 25 improved the retinal thickness as seen 
with increase in thickness of the ONL and the 
distance between the OLM and ILM.  
 
Figure 2. Effect of four week treatment with NOB10 and NOB25 on 
retinal thickness. * p < 0.05, ** p<0.01 vs vehicle treated diabetic rats. 
(n = 6 for all groups). OLM -ILM (Outer Limiting Membrane to Inner 
Limiting Membrane), ONL (Outer Nuclear Layer). 
 
Several research studies suggest the role of 
matrix metalloproteinases (MMPs) in the development 
of diabetic retinopathy.19  It is clearly understood that 
latent MMPs are activated in the retina and its capillary 
cells on prolonged hyperglycemia in diabetes mellitus 
and over activation of MMPs, specifically MMP-2 and 
-9 induces apoptosis of retinal capillary cells leading to 
retinal damage. MMPs have an important role in 
maintaining the integrity of the blood–retinal barrier 
(BRB). Increased retinal MMPs in diabetes facilitate 
the increase in vascular permeability via proteolytic 
degradation of the tight junction protein occludin and 
disruption of the overall tight junction complex.20 
Pharmacological inhibition of MMPs is shown to 
prevent retinal and choroidal neovascularisation21 and 
inhibit MMP-9-mediated retinal vascular permeability 
and inflammation.22 In another study, administration 
of a synthetic MMP inhibitor prevented the induction 
of proliferative vitreoretinopathy.23 MMP-2 and MMP-
9 inhibition in presence of COX inhibitor has also 
shown to prevent retinal abnormalities.24 We 
hypothesized that nobiletin, a flavonoid from citrus 
fruits, could be beneficial in the treatment of diabetic 
retinopathy. Nobiletin possesses MMP-2 and MMP-9 
inhibitory activity. In our previous study, we reported 
decreased serum MMP-2 and MMP-9 levels by 
nobiletin treatment in diabetic rats.25 In the present 
study, treatment with nobiletin in STZ induced DR 
showed improvement in the condition. Thus, nobiletin 
can ameliorate diabetic retinopathy on long term 
administration. This activity of nobiletin can be 
attributed to its MMP inhibitory property.   
In conclusion, present study showed efficacy 
of nobiletin and indicated that nobiletin can be a 
potential molecule in the treatment of diabetic 
retinopathy. 
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